Cryo-EM Structure of a Triazole alpha-Conotoxin GI Mimetic Bound to the Muscle-Type Nicotinic Acetylcholine Receptor

The human body relies on a constant, rapid conversation between nerve cells and muscles to make movement possible. This conversation happens at tiny junctions where chemical messengers, released by nerves, bind to specific receptors on the muscle surface. One of the most important of these receptors is the muscle-type nicotinic acetylcholine receptor, a molecular gate that opens to let signals pass through, telling the muscle to contract. When this system works correctly, we can walk, breathe, and grasp objects. When it malfunctions or is blocked by toxins, movement fails. Scientists have long studied natural compounds that can bind to these receptors with extreme precision, hoping to understand their shape and function well enough to create new medicines. Among the most potent of these natural compounds are small peptides found in the venom of cone snails, which act like highly specialized keys designed to fit into the locks of these receptors. However, these natural keys are fragile; their structure depends on chemical bridges that are easily broken, making them difficult to store, synthesize, or use as stable drugs.

Researchers set out to solve this problem of fragility by redesigning one of these natural keys, known as the alpha-conotoxin GI, which is a selective blocker of the muscle-type receptor. The natural version of this peptide holds its shape together using a specific bridge formed between two sulfur-containing amino acids. To make a more stable version, the team replaced this sulfur bridge with a different chemical structure called a triazole, a ring of atoms that mimics the shape and spacing of the original bridge but is much harder to break. They built these new molecules entirely by hand, using chemical reactions to stitch the pieces together on a solid support, creating two main types of replacements: one with a specific arrangement of atoms called 1,4-disubstituted and another called 1,5-disubstituted. The goal was to see if these artificial replacements could hold the peptide in the correct shape and still bind to the receptor with the same strength as the natural venom.

When the team tested these new molecules against human muscle receptors, the results showed that the arrangement of the atoms mattered deeply. The version with the 1,5-arrangement performed remarkably well, binding to the receptor with a potency in the low-nanomolar range, which is comparable to the strength of the original, natural peptide. In contrast, the other arrangement did not perform as effectively. This confirmed that the specific geometry of the 1,5-triazole ring was the key to maintaining the correct shape. To understand exactly how this worked, the researchers used a powerful imaging technique called cryo-electron microscopy to take a direct, high-resolution picture of the lead molecule sitting inside the receptor. This provided the first clear view of a peptide that uses a non-sulfur bridge bound to a membrane receptor.

The images revealed that the artificial molecule fits into the receptor almost exactly as the natural one does. The triazole ring successfully held the peptide in its native fold, preserving the overall shape required for the drug to work. However, the structure also showed something unexpected: the triazole ring itself reached out and made new contacts with the receptor that the original sulfur bridge could not make. These extra interactions suggest that the artificial molecule might bind even more securely in some ways. To further verify this, the team ran computer simulations that modeled the movement of the molecules over time. These simulations showed that the water molecules surrounding the peptide and the receptor behaved in a very similar way for both the natural and the artificial versions, and that the molecule wobbled and shifted in the same patterns. The study concludes that triazoles can serve as effective stand-ins for sulfur bridges, offering a way to stabilize these powerful peptides without losing their ability to interact with their targets, providing a solid structural foundation for designing future, more stable therapeutics.